Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Manatee
    4. ›
  4. Sarasota
    5. ›
  5. THE ROSKAMP INSTITUTE, INC.

THE ROSKAMP INSTITUTE, INC. - Florida Company Profile

Company claim

Is this your business?

Get access!

Company Details

Entity Name: THE ROSKAMP INSTITUTE, INC.
Jurisdiction: FLORIDA
Filing Type: Domestic Non-Profit
Status: Active
Date Filed: 24 Feb 2010 (16 years ago)
Document Number: N10000001959
FEI/EIN Number 271397124
Address: 2040 WHITFIELD AVE, SARASOTA, FL, 34243
Mail Address: 2040 WHITFIELD AVE, SARASOTA, FL, 34243
ZIP code: 34243
City: Sarasota
County: Manatee
Place of Formation: FLORIDA

Key Officers & Management

Name Role Address
CARTER CYNTHIA Treasurer 2040 WHITFIELD AVE, SARASOTA, FL, 34243
SABBATO DAWN Secretary 2040 WHITFIELD AVE, SARASOTA, FL, 34243
CRAWFORD FIONA D Chief Executive Officer 2040 WHITFIELD AVENUE, SARASOTA, FL, 34243
The Roskamp Institute Agent 2040 WHITFIELD AVE, SARASOTA, FL, 34243

Unique Entity ID

Unique Entity ID:
V17JAHQF87A1
CAGE Code:
6FVY7
UEI Expiration Date:
2025-12-04

Business Information

Doing Business As:
ROSKAMP INSTITUTE
URL:
https://www.roskampinstitute.org/
Division Name:
THE ROSKAMP INSTITUTE, INC.
Activation Date:
2024-12-06
Initial Registration Date:
2011-07-05

Commercial and government entity program

CAGE number:
6FVY7
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2024-12-06
CAGE Expiration:
2029-12-06
SAM Expiration:
2025-12-04

Contact Information

POC:
DAWN SABBATO
Corporate URL:
https://www.roskampinstitute.org/

National Provider Identifier

NPI Number:
1801169792
Link:
View on NPI website

Authorized Person:

Name:
NANCY P KAVANAGH
Role:
OFFICE MANAGER
Phone:
9412568019

Taxonomy:

Selected Taxonomy:
174400000X - Specialist
Is Primary:
Yes

Contacts:

Phone:
+1 941-256-8019
Fax:
9417563681

Events

Event Type Filed Date Value Description
REGISTERED AGENT NAME CHANGED 2020-06-25 The Roskamp Institute -
REGISTERED AGENT ADDRESS CHANGED 2018-05-09 2040 WHITFIELD AVE, SARASOTA, FL 34243 -

Documents

Name Date
ANNUAL REPORT 2024-05-24
ANNUAL REPORT 2023-03-23
ANNUAL REPORT 2022-01-25
ANNUAL REPORT 2021-02-15
ANNUAL REPORT 2020-06-25
ANNUAL REPORT 2019-01-16
ANNUAL REPORT 2018-05-09
ANNUAL REPORT 2017-01-13
ANNUAL REPORT 2016-03-08
ANNUAL REPORT 2015-02-10

USAspending Awards / Contracts

Procurement Instrument Identifier:
36C24824N1197
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
DELIVERY ORDER
Action Obligation:
34000.00
Base And Exercised Options Value:
34000.00
Base And All Options Value:
170000.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2024-09-19
Description:
TASK ORDER FROM IDC BASE YEAR
Naics Code:
541990: ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES
Product Or Service Code:
AN41: HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
Procurement Instrument Identifier:
36C24824D0111
Link:
View Award on USAspending website
Award Or Idv Flag:
IDV
Action Obligation:
0.00
Base And All Options Value:
170000.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2024-09-19
Description:
IDIQ ANIMAL RESEARCH AND SUPPORT CONTRACT BASE YEAR
Naics Code:
541990: ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES
Product Or Service Code:
AN41: HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
Procurement Instrument Identifier:
36C24822P1308
Link:
View Award on USAspending website
Award Or Idv Flag:
AWARD
Award Type:
PURCHASE ORDER
Action Obligation:
16020.00
Base And Exercised Options Value:
16020.00
Base And All Options Value:
0.00
Awarding Agency Name:
Department of Veterans Affairs
Performance Start Date:
2022-07-01
Description:
IGF CT IGF CRITICAL FUNCTION VETERINARY MAINTENANCE ERVICE
Naics Code:
541940: VETERINARY SERVICES
Product Or Service Code:
R416: SUPPORT- PROFESSIONAL: VETERINARY/ANIMAL CARE

USAspending Awards / Financial Assistance

Date:
2025-05-27
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
DELINEATING THE THERAPEUTIC EFFECT OF A NOVEL BBB-PENETRABLE PPAR AGONIST ON CHRONIC OUTCOMES FOLLOWING AGE-RELATED REPETITIVE MILD TBI
Obligated Amount:
3268799.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-12-20
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
TARGETING THE ASTROCYTE-CEREBROVASCULATURE SYSTEM TO CORRECT BRAIN BIOENERGETICS DEFECTS ASSOCIATED WITH APOE4 - THE APOLIPOPROTEIN E4 (APOE4) ALLELE IS THE MAJOR GENETIC RISK FACTOR FOR ALZHEIMER'S DISEASE (AD), A NEURODEGENERATIVE CONDITION MARKED BY IMPAIRMENT OF THE BRAIN BIOENERGETICS. ENERGY DYNAMICS IN THE BRAIN ARE TIGHTLY LINKED TO NEURONAL ACTIVITY AND HAVE A MAJOR IMPACT ON NEURONAL FUNCTION. GLUCOSE IS THE MAIN SOURCE OF ENERGY FOR THE BRAIN, AND ITS CEREBRAL FUELING IS GUARANTEED BY GLUCOSE TRANSPORTERS WITHIN THE BRAIN VASCULAR SYSTEM. GLUCOSE IS DIRECTLY CONSUMED BY NEURONS OR CAN BE METABOLIZED BY ASTROCYTES INTO LACTATE, WHICH IS THEN EXPORTED TO NEURONS AS A SUPPLEMENTARY ENERGY SOURCE. WHEN GLUCOSE SUPPLY TO THE BRAIN FROM THE BLOOD IS INSUFFICIENT, ASTROCYTES CAN ALSO GENERATE FATTY ACID (FA) METABOLITES THROUGH MITOCHONDRIAL FATTY ACID (FA) Β- OXIDATION (FAO) AND THESE METABOLITES SERVE AS ALTERNATIVE ENERGY SUBSTRATES FOR NEURONS. APOE4-MEDIATED DISTURBANCES OF THE FAO HAVE BEEN OBSERVED IN CELLS AT THE BLOOD BRAIN BARRIER (BBB) AND ASSOCIATED WITH ALTERATIONS IN THE BBB INTEGRITY SUGGESTING THAT PERTURBATIONS OF THE ENERGY METABOLISM OF THESE CELLS COULD LEAD TO DEFICITS OF NEURONAL ENERGY SUPPLY IN E4 CARRIERS. OUR PREVIOUS WORK SHOWED THE AMP-ACTIVATED PROTEIN KINASE (AMPK)-MEDIATED ACETYL-COA CARBOXYLASE ACTIVATION IS AFFECTED IN THE CEREBROVASCULATURE OF APOE4-TR AND E4FAD MICE, WITH CHANGES MORE PRONOUNCED IN THE PRESENCE OF AD PATHOLOGY IN EFAD MICE. AS THIS SYSTEM PLAYS A KEY ROLE IN LINKING GLUCOSE UPTAKE AND METABOLISM WITH FAO, WE HYPOTHESIZE THAT BRAIN BIOENERGETICS DEFICITS IN E4 CARRIERS, AND MORE IMPORTANTLY IN THE PRESENCE OF AD-RELATED INSULTS, RESULT FROM A COMBINATION OF LOW GLUCOSE AVAILABILITY DUE TO ITS POOR TRANSIT ACROSS THE BBB, PARTICULARLY THROUGH THE CEREBROVASCULATURE (CV), AND THEIR REDUCED ABILITY TO SWITCH TOWARDS COMPENSATORY MECHANISMS TO MEET BRAIN BIOENERGETIC NEEDS. THIS COULD BE MEDIATED BY AN INHIBITION OF THE GLP-1R-AMPK-ACC PATHWAY IN THE E4-CV/ASTROCYTE CROSSTALK SYSTEM, WHICH WOULD LOWER THE FAO IN THESE CELLS AND ALTER THEIR CAPACITY TO MAINTAIN BRAIN BIOENERGETIC HOMEOSTASIS. TARGETING THE GLP-1R-AMPK-ACC PATHWAY IN E4 CV/ASTROCYTES COULD SERVE AS A PROMOTER OF THE FAO TO CORRECT THE BIOENERGETICS IMBALANCE IN E4 CARRIERS. HOWEVER, THE IMPACT OF MODULATING THIS PATHWAY IN THE CV AND ASTROCYTES HAS NOT YET BEEN FULLY INVESTIGATED. HENCE, USING AN AD MOUSE MODEL, WE WILL EXAMINE THE INFLUENCE OF DIFFERENT APOE GENOTYPES ON THE GLP-1R-AMPK-ACC PATHWAY IN CV AND ASTROCYTES. WE WILL ALSO DETERMINE WHETHER TREATMENTS THAT INDUCE ACTIVATION OF THE GLP-1R-AMPK-ACC PATHWAY COULD REGULATE FAO IN E4 CARRIERS, WHICH COULD OPEN THE DOOR TO NEW WAYS OF TREATING AD. THUS, THESE PROPOSED STUDIES WILL PROVIDE CRITICAL INSIGHT INTO THE DEVELOPMENT OF APPROACHES FOR TARGETING BRAIN BIOENERGETIC PATHWAYS TO PREVENT OR REDUCE COGNITIVE DECLINE IN AD AMONG HIGH-RISK APOE E4 CARRIERS.
Obligated Amount:
341000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-08-27
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
INFLUENCE OF MICROGLIAL CELL DEPLETION AND REPOPULATION ON ADUCANUMAB INDUCED ARIA AND VASCULAR LESIONS IN APOE4 CARRIERS WITH AD - AFTER MANY FAILED CLINICAL TRIALS, THE FDA RECENTLY APPROVED NEW BREAKTHROUGH ANTIBODY THERAPY FOR USE IN EARLY AD. BUT THESE THERAPIES HAVE BEEN REVEALED TO INCREASE THE FREQUENCY OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIAS). IMPORTANTLY, ARIA OCCURS MORE FREQUENTLY IN APOE4 CARRIERS. ALTHOUGH THE MECHANISM IS UNCLEAR, ARIA IS THOUGHT TO OCCUR AFTER REMOVAL OF AMYLOID FROM BLOOD VESSELS WITH CEREBRAL AMYLOID ANTIPATHY (CAA). APOE4 ALLELE IS ONE OF THE STRONGEST RISK FACTORS FOR AD AND HAS BEEN SHOWN TO PROMOTE CEREBROVASCULAR LESIONS SUCH AS CAA AND MICROHEMORRHAGES. BECAUSE CAA IS UNIVERSALLY OBSERVED IN AD, FURTHER INVESTIGATION OF APOE4-DEPENDENT MECHANISMS DRIVING CAA AND ARIA-EVENTS IS NEEDED. ACTIVATED MICROGLIA HAVE BEEN SHOWN TO DRIVE THE OUTCOME AND PACE OF APOE-MEDIATED NEURODEGENERATION. IMPORTANTLY, MICROGLIA CAN MODULATE CEREBROVASCULAR INTEGRITY AND CEREBRAL BLOOD FLOW, AND RELEASE FACTORS WHICH CONTRIBUTE TO BBB BREAKDOWN, CEREBROVASCULAR CELL DAMAGE AND NEUROVASCULAR INJURY. IN OUR STUDIES, WE REVEALED AN INCREASE IN INFLAMMATORY PATHWAYS IN AD VS CONTROL HUMAN CEREBROVESSELS, AND THIS WAS MORE PROMINENT IN APOE4 CARRIERS, WHO ALSO HAD HIGHER CAA SCORES. ANTI-AΒ ANTIBODY RELATED ARIA HAS ALSO BEEN ASSOCIATED WITH REACTIVE MICROGLIOSIS IN A PRIMATE MODEL OF CAA. IN HUMANS, IN VIVO PET IMAGING OF MICROGLIAL ACTIVATION HAS BEEN ASSOCIATED WITH THE MAGNITUDE AND SEVERITY OF ARIA. NO PRECLINICAL MODELS HAVE EVALUATED THIS ASSOCIATION BETWEEN ACTIVATED MICROGLIA RESPONSE AND ARIA-EVENTS, PARTICULARLY IN THE CONTEXT OF APOE4 GENOTYPE. IN THIS PROPOSAL, WE WILL ADDRESS THESE UNKNOWNS BY UTILIZING MICROGLIAL ABLATION AND REPOPULATION TECHNIQUES IN A PREVIOUSLY DESCRIBED CHRONIC ANTI-AΒ TREATED EFAD MOUSE MODEL OF AD EXPRESSING HUMAN APOE ISOFORMS AND AD MUTATIONS (I.E., ADUCANUMAB TREATED E3FAD AND E4FAD MICE). FROM THESE STUDIES, WE WILL GENERATE A DETAILED TIME-COURSE OF COGNITIVE FUNCTION, CEREBRAL BLOOD FLOW AND CEREBROVASCULAR REACTIVITY, AND CHARACTERIZE THE HISTOPATHOLOGICAL AND BIOCHEMICAL LEVEL CHANGES TO THE CEREBROVASCULATURE. NO STUDIES HAVE CHARACTERIZED THE CEREBROVASCULAR CELL PHENOTYPES IN ARIA PATIENTS. WE WILL THUS EMPLOY A SINGLE CELL TRANSCRIPTOMIC APPROACH TO CHARACTERIZE THE PHENOTYPIC BRAIN VASCULAR CELL TYPE RESPONSE(S) IN OUR EFAD MODELS FOLLOWING ADUCANUMAB TREATMENT WITH/WITHOUT MACROPHAGE DEPLETION AND REPOPULATION, AND REVEAL KEY UPSTREAM REGULATORS DRIVING THESE UNIQUE VASCULAR CELL RESPONSES AT THE SINGLE CELL LEVEL. FROM THIS PROPOSAL, OUR GOAL IS TO REVEAL WHETHER ACTIVATED MICROGLIA MEDIATED CEREBROVASCULAR INFLAMMATION CONTRIBUTES TO APOE4 MEDIATED ARIA EVENTS FOLLOWING ADUCANUMAB TREATMENT, AND II) IDENTIFY NOVEL TARGETS THROUGH WHICH APOE4 CONFERS THESE VASCULAR-SPECIFIC ABNORMALITIES, TO REVEAL NEW OPPORTUNITIES FOR IMPROVED ANTIBODIES AND ADJUNCT THERAPIES THAT CAN ONE DAY MINIMIZE THESE COMPLICATIONS IN APOE4 PATIENTS WITH AD.
Obligated Amount:
213125.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-08-22
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NEUROLOGICAL EFFECTS OF AEROSOLIZED RED TIDE NEUROTOXINS - THE OBSERVED INCREASED OCCURRENCES OF HARMFUL ALGAL BLOOMS (HABS) ARE LARGELY A CONSEQUENCE OF OCEAN WARMING DUE TO CLIMATE CHANGE, EUTROPHICATION, AND NUTRIENT POLLUTION, WHICH RAISE CONCERNS THAT HABS ARE NEGATIVELY IMPACTING AQUATIC ECOSYSTEMS, COASTAL RESOURCES AND THE HEALTH OF COASTAL COMMUNITIES. AMONG THESE HABS, KARENIA (K.) BREVIS AFFECTS MANY GULF COAST COMMUNITIES, PARTICULARLY SOUTHWEST FLORIDA. OVER THE LAST DECADE, K. BREVIS BLOOMS HAVE CAUSED MASSIVE DESTRUCTION TO MARINE LIFE AND MORBIDITY AND MORTALITY OF MARINE MAMMALS. THESE HARMFUL EFFECTS OF K. BREVIS ARE ATTRIBUTED TO THE RELEASE OF POTENT NEUROTOXINS, BREVETOXINS (PBTX). CURRENTLY, THE IMPACT OF AEROSOLIZED PBTX EXPOSURE ON THE HUMAN CENTRAL NERVOUS SYSTEM (CNS) IS NOT YET KNOWN. HUMAN CONSUMPTION OF PBTX CAUSES NEUROTOXIC SHELLFISH POISONING (NSP), INCLUDING A WIDE RANGE OF NEUROLOGICAL SYMPTOMS. WE RECENTLY SHOWED THAT SW FLORIDA RESIDENTS EXPOSED TO AEROSOLIZED PBTX ARE EXPERIENCING NSP-LIKE (NSPL) SYMPTOMS, AND THOSE WITH PAST MEDICAL HISTORIES (PMHX) OF MIGRAINE AND CHRONIC FATIGUE SYNDROME (CFS) WERE PARTICULARLY VULNERABLE TO THE NEUROLOGICAL EFFECTS OF AEROSOLIZED PBTX. CARRIERS OF THE APOLIPOPROTEIN E (APOE) E4 ALLELE WHO ARE GENETICALLY AT A HIGHER RISK OF COGNITIVE IMPAIRMENT MORE FREQUENTLY EXPERIENCE MEMORY PROBLEMS AND FATIGUE DURING RED TIDE BLOOMS. WE HAVE DETECTED PBTX IN BLOOD, AND ANTIBODIES AGAINST PBTX CORRESPOND WITH THE REPORTING OF NSPL SYMPTOMS FOLLOWING EXPOSURE TO AEROSOLIZED PBTX. HOWEVER, A DOSE-RESPONSE RELATIONSHIP BETWEEN AEROSOLIZED PBTX EXPOSURE AND THE EMERGENCE OF NSPL AND NEUROLOGICAL SYMPTOMS IS CURRENTLY UNKNOWN. THEREFORE, WE WILL DETERMINE A DOSE-RESPONSE RELATIONSHIP BETWEEN AEROSOLIZED PBTX EXPOSURE AND NSPL AND NEUROLOGICAL SYMPTOMS. WE WILL DETERMINE WHETHER INDIVIDUALS WITH PREEXISTING NEUROLOGICAL CONDITIONS OR E4 CARRIERS MORE FREQUENTLY EXPERIENCE NSPL COMPARED TO GENERAL RESIDENTS AND NON-CARRIERS. WE WILL ALSO DETERMINE WHETHER PBTX IN BIOSPECIMENS AND BLOOD PBTX ANTIBODIES CAN SERVE AS BIOMARKERS OF NSPL AND NEUROLOGICAL SYMPTOMS. CURRENTLY, THERE IS NO INFORMATION AVAILABLE ON PBTX PHARMACOKINETICS (PK) IN HUMANS. THEREFORE, WE WILL DETERMINE THE PK PARAMETERS USING PBTX IN BIOSPECIMENS AND DETERMINE THEIR RELATIONSHIP TO NSPL AND NEUROLOGICAL SYMPTOMS. USING PHYSIOLOGY-BASED PK MODELING, WE WILL ESTIMATE THE AMOUNTS OF PBTX THAT CAN REACH THE HUMAN BRAIN, WHICH WILL BE CRITICAL FOR UNDERSTANDING THE ADVERSE BRAIN HEALTH EFFECTS FROM AEROSOLIZED PBTX EXPOSURE. THIS WORK WILL INFORM FUTURE DECISION-MAKING FOR DEVELOPING STRATEGIES TO MINIMIZE THE RISKS OF NEUROLOGICAL SYMPTOMS IN HUMANS FOLLOWING AEROSOLIZED PBTX EXPOSURE. GIVEN THE ONGOING THREAT OF CLIMATE CHANGE ON THE FORMATION OF POWERFUL HURRICANES IN THE PACIFIC AND ATLANTIC OCEANS AND THE GULF OF MEXICO AND SUBSEQUENT OCCURRENCES OF INTENSE HABS IN COASTAL WATERS, THIS POPOSED WORK WILL PROVIDE A ROADMAP FOR FUTURE INVESTIGATIONS INTO STUDYING THE ADVERSE HUMAN HEALTH IMPACT FROM EXPOSURE TO HAB TOXINS.
Obligated Amount:
704695.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2024-07-08
Link:
View on USAspending
Awarding Agency Name:
Department of Defense
Transaction Description:
TARGETING APOE BIOENERGETICS FOR REDUCING THE RISK OF NEURODEGENERATION AFTER CHRONIC TRAUMATIC BRAIN INJURY
Obligated Amount:
817200.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Tax Exempt

Employer Identification Number (EIN) :
27-1397124
In Care Of Name:
% SUSAN THOMPSON
Classification:
Educational Organization, Local Association of Employees, Horticultural Organization, Business League, Voluntary Employees' Beneficiary Association (Govt. Emps.), Mutual Ditch or Irrigation Co., Cemetery Company, Other Mutual Corp. or Assoc.
Ruling Date:
2011-01
National Taxonomy Of Exempt Entities:
Medical Research: Medical Research N.E.C.
Deductibility:
Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Determination Letters

Link:
Download file
Link:
Download file

Paycheck Protection Program

Jobs Reported:
56
Initial Approval Amount:
$527,979
Date Approved:
2021-02-24
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$527,979
Race:
White
Ethnicity:
Unknown/NotStated
Gender:
Female Owned
Veteran:
Non-Veteran
Forgiveness Amount:
$534,025.44
Servicing Lender:
Synovus Bank
Use of Proceeds:
Payroll: $527,977
Utilities: $1
Jobs Reported:
56
Initial Approval Amount:
$527,979
Date Approved:
2020-04-13
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$527,979
Race:
White
Ethnicity:
Unknown/NotStated
Gender:
Female Owned
Veteran:
Non-Veteran
Forgiveness Amount:
$533,490.23
Servicing Lender:
Synovus Bank
Use of Proceeds:
Payroll: $527,979

Reviews Leave a review

This company hasn't received any reviews.

Related by address

2040 WHITFIELD AVE, SARASOTA, FL, 34243

GOLDENROD COMMERCE PARK, LLC
Florida Limited Liability Co.
GOLDENROD COMMERCE PARK, LLC, which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.
ARCHER PHARMACEUTICALS, INC.
Foreign Profit
ARCHER PHARMACEUTICALS, INC., which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.
ARCHER PHARMACEUTICALS, INC.
Foreign Profit
ARCHER PHARMACEUTICALS, INC., which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.

2040 WHITFIELD AVE, SARASOTA, FL, 34243

GOLDENROD COMMERCE PARK, LLC
Florida Limited Liability Co.
GOLDENROD COMMERCE PARK, LLC, which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.
ARCHER PHARMACEUTICALS, INC.
Foreign Profit
ARCHER PHARMACEUTICALS, INC., which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.
ARCHER PHARMACEUTICALS, INC.
Foreign Profit
ARCHER PHARMACEUTICALS, INC., which currently Inactive, had registered address 2040 WHITFIELD AVE, SARASOTA, FL, 34243.

Date of last update: 03 Aug 2025

Sources: Florida Department of State

Privacy policy Policy
About us About us Business Directory
Contacts Contact us

© 2025 flprofile.com, Part of Big Data Integrated